Literature DB >> 32060842

CCL3 Signaling in the Tumor Microenvironment.

Ioannis Ntanasis-Stathopoulos1, Despoina Fotiou1, Evangelos Terpos2.   

Abstract

Within the tumor microenvironment, chemokines play a key role in immune cell trafficking regulation and immune landscape formulation. CCL3 or macrophage inflammatory protein-1α (MIP-1α), an important chemokine implicated in both immune surveillance and tolerance, has emerged as a prognostic biomarker in both solid and hematological malignancies. CCL3 exerts both antitumor and pro-tumor behavior which is context dependent highlighting the complexity of the underlying interrelated signaling cascades. Current CCL3-directed therapeutic approaches are investigational and further optimization is required to increase efficacy and minimize adverse events.

Entities:  

Keywords:  CCL2; CCL3; CCR1; CCR4; CCR5; Chemokine; Chemokines; Immune cell; Lymph node; MIP-1a; Macrophage inflammatory protein-1 alpha; Metastasis-associated macrophages; T cell; Tumor microenvironment; Tumor-associated macrophages

Mesh:

Substances:

Year:  2020        PMID: 32060842     DOI: 10.1007/978-3-030-36667-4_2

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  20 in total

Review 1.  Payload Delivery: Engineering Immune Cells to Disrupt the Tumour Microenvironment.

Authors:  Daniel Fowler; Callum Nattress; Alba Southern Navarrete; Marta Barisa; Jonathan Fisher
Journal:  Cancers (Basel)       Date:  2021-11-29       Impact factor: 6.639

2.  Identification and validation of an immunological microenvironment signature and prediction model for epstein-barr virus positive lymphoma: Implications for immunotherapy.

Authors:  Chenjiao Yao; Ruoyao Xu; Qianyuan Li; Sheng Xiao; Min Hu; Linyong Xu; Quan Zhuang
Journal:  Front Oncol       Date:  2022-09-29       Impact factor: 5.738

3.  A Selective β-Catenin-Metadherin/CEACAM1-CCL3 Axis Mediates Metastatic Heterogeneity upon Tumor-Macrophage Interaction.

Authors:  Sally K Y To; Maggie K S Tang; Yin Tong; Jiangwen Zhang; Karen K L Chan; Philip P C Ip; Jue Shi; Alice S T Wong
Journal:  Adv Sci (Weinh)       Date:  2022-04-11       Impact factor: 17.521

4.  Transcriptome Reprogramming of CD11b+ Bone Marrow Cells by Pancreatic Cancer Extracellular Vesicles.

Authors:  Joana Maia; Andreia Hanada Otake; Juliana Poças; Ana Sofia Carvalho; Hans Christian Beck; Ana Magalhães; Rune Matthiesen; Maria Carolina Strano Moraes; Bruno Costa-Silva
Journal:  Front Cell Dev Biol       Date:  2020-11-27

5.  Inducible Sbds deletion impairs bone marrow niche capacity to engraft donor bone marrow after transplantation.

Authors:  Ji Zha; Lori K Kunselman; Hongbo M Xie; Brian Ennis; Yash B Shah; Xia Qin; Jian-Meng Fan; Daria V Babushok; Timothy S Olson
Journal:  Blood Adv       Date:  2022-01-11

Review 6.  Tumor Associated Macrophages: Origin, Recruitment, Phenotypic Diversity, and Targeting.

Authors:  Tetiana Hourani; James A Holden; Wenyi Li; Jason C Lenzo; Sara Hadjigol; Neil M O'Brien-Simpson
Journal:  Front Oncol       Date:  2021-12-20       Impact factor: 6.244

7.  Immune-Proteome Profiling in Classical Hodgkin Lymphoma Tumor Diagnostic Tissue.

Authors:  Alex Reza Gholiha; Peter Hollander; Liza Löf; Anders Larsson; Jamileh Hashemi; Johan Mattsson Ulfstedt; Daniel Molin; Rose-Marie Amini; Eva Freyhult; Masood Kamali-Moghaddam; Gunilla Enblad
Journal:  Cancers (Basel)       Date:  2021-12-21       Impact factor: 6.639

8.  IP-10 and MCP-1 as biomarkers associated with disease severity of COVID-19.

Authors:  Yu Chen; Jinglan Wang; Chenxi Liu; Longxiang Su; Dong Zhang; Junping Fan; Yanli Yang; Meng Xiao; Jing Xie; Yingchun Xu; Yongzhe Li; Shuyang Zhang
Journal:  Mol Med       Date:  2020-10-29       Impact factor: 6.354

Review 9.  Pathogenic Mechanisms of Myeloma Bone Disease and Possible Roles for NRF2.

Authors:  Chia-Hung Yen; Chin-Mu Hsu; Samuel Yien Hsiao; Hui-Hua Hsiao
Journal:  Int J Mol Sci       Date:  2020-09-14       Impact factor: 5.923

10.  Carfilzomib Improves Bone Metabolism in Patients with Advanced Relapsed/Refractory Multiple Myeloma: Results of the CarMMa Study.

Authors:  Evangelos Terpos; Ioannis Ntanasis-Stathopoulos; Eirini Katodritou; Marie-Christine Kyrtsonis; Vassiliki Douka; Emmanouil Spanoudakis; Athanasios Papatheodorou; Evangelos Eleutherakis-Papaiakovou; Nikolaos Kanellias; Maria Gavriatopoulou; Polyzois Makras; Efstathios Kastritis; Meletios A Dimopoulos
Journal:  Cancers (Basel)       Date:  2021-03-12       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.